Solid Biosciences (SLDB) stock retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne Muscular Dystrophy [DMD]. Read the full analysis here.
"As we prepare to commence the Phase1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, we're excited to present new preclinical data highlighting its potential to deliver durable, long-term functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results